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http://www.lipidworld.com/content/13/1/63RESEARCH Open AccessA combination of flaxseed oil and astaxanthin
alleviates atherosclerosis risk factors in high fat
diet fed rats
Jiqu Xu1,2, Hui Gao3, Li Zhang4, Chang Chen5,6, Wei Yang3, Qianchun Deng1,2, Qingde Huang1,2
and Fenghong Huang1,2*Abstract
Background: Atherosclerosis is the most common pathologic process underlying cardiovascular disease. Both
flaxseed oil (FO) and astaxanthin (ASX) are believed to benefit cardiovascular system. The combined effect of FO
and ASX on the atherosclerosis risk factors in rats fed a high-fat diet was investigated.
Methods: Astaxanthin was dissolved in flaxseed oil to a final concentration of 1 g/kg (FO + ASX). Male Sprague–Dawley
rats were fed a rodent diet contained 20% fat whose source was lard (HFD) or 75% lard and 25% FO + ASX (50 mg
ASX/kg diet) or 50% lard and 50% FO + ASX (100 mg ASX/kg diet) or FO + ASX (200 mg ASX/kg diet) for 10 weeks.
Results: The combination of FO and ASX significantly increased the antioxidant defense capacity and decreased lipid
peroxidation in plasma. Evident decreases in the levels TG, TC and LDL-C contents, as well as IL-6 and CRP were also
observed in plasma of FO and ASX fed rats.
Conclusion: The combination of FO and ASX can improve oxidative stress, lipid abnormalities and inflammation,
providing evidence that the combination of FO and ASX could be a promising functional food in cardiovascular health
promotion.
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Nowadays, cardiovascular disease (CVD) is the leading
cause of morbidity and mortality in most developed as
well as many developing countries [1,2] and contributes
substantially to healthcare budgets. Atherosclerosis is a
chronic, progressive and systemic pathologic process
and the primary contributing factor to CVD. Research
into atherosclerosis has led to many compelling disco-
veries about the mechanism of the disease. There are de-
finitive evidences to show that oxidant stress [3], lipid
abnormalities [4] as well as chronic inflammation [5]* Correspondence: fhhuang@foxmail.com
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unless otherwise stated.have a crucial involvement in both the initiation and the
progression of atherosclerosis.
Flaxseed oil (FO) is one of the most important spe-
cialty oils, which contains high levels of α-linolenic acid
(ALA, 18:3 n-3). Higher intake of ALA has been long
recognized as a “good nutritional intervention” with in-
creasing many health benefits. As an essential polyun-
saturated fatty acid (PUFA) that cannot be synthesized
by human being, ALA serves as a precursor for long-
chain n–3 polyunsaturated fatty acids such as eicosa-
pentaenoic acid (EPA) and docosahexaenoic acid (DHA).
Furthermore, ALA itself may exert various biological
functions by competing with linoleic acid or interaction
with ion channels and nuclear receptors [6]. ALA has
been widely reported to have many beneficial effects on
blood lipid profiles [6-9] and inflammation [6,10,11],
which suggest that FO are beneficial for atherosclerosis
prevention. However, on the other hand, since ALA is
highly susceptible to oxidation, FO addition leads to aThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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dation [12,13], which may have an adverse effect on the
protection of cardiovascular system.
Astaxanthin (ASX) is a lipophilic xanthophyll caroten-
oid and found in a variety of living organism including
microalgae, fungi and crustaceans. It features a unique
molecular structure which confers this natural product a
powerful antioxidant activity [14]. In recent years, a large
body of evidence has revealed a wide range of biological
effects such as anti-cancer, anti-diabetes and neuropro-
tective actions [14,15]. In addition, ASX has also been
reported to reduce blood pressure, LDL oxidation as
well as inflammatory [14-17], and thus, combining its
protection against oxidative stress, provides overall car-
diovascular benefits.
Up to now, the effects of the combination of FO and
ASX on cardiovascular system have not been investi-
gated. In this study, we try to determine whether the
combination of FO and ASX is able to reduce athero-
sclerosis risk factors in rats fed a high-fat diet.
Materials and methods
Chemical sources
The flaxseed oil was purchased from Caoyuankangshen
Food Co., Ltd (Inner Mongolia, China). Astaxanthin ex-
tracted from microalga Haematococcus pluvialis was dis-
solved and diluted in flaxseed oil to a final concentration
of 1 g/kg (FO + ASX). Commercial deodorized lard was
purchased from a local supermarket.
Animals and diets
Forty male Sprague–Dawley rats (initially weighing 150–
170 g) were purchased from Sino-British Sippr/BK
(Shanghai, China). The animals were housed individually
and maintained at a controlled ambient temperature
(22 ± 1°C) under diurnal conditions (light–dark: 08:00–
20:00) with access to laboratory chow and tap water ad
libitum. After 1 week of acclimatization, rats were ran-
domly divided into a high-fat diet (HFD) group and three
experimental groups of 10 animals each. All animals were
fed purified experimental diets which contained 35%
maize starch, 20% casein, 15% sucrose, 5% cellulose, 3.5%
mineral mixture (AIN-93M), 1% vitamin mixture (AIN-
93M), 0.3% DL-methionine, 0.2% choline bitartrate and
20% fat. The fat in the diet of each group was provided by
either lard (HFD group), or 75% lard and 25% FO +ASX
(50 mg ASX/kg diet, L-FO +ASX group), or 50% lard and
50% FO+ASX (100 mg ASX/kg diet, M-FO +ASX group),
or FO +ASX (200 mg ASX/kg diet, H-FO +ASX group).
Every week, all ingredients for the purified diets were
mixed, formed into a dough with purified water, rolled
into pellets, sealed in air-tight plastic bags under nitrogen
gas and stored at -80°C until use. The food in the animal
cages was shaded from light and changed every day. Theanimals were cared for in accordance with the Guiding
Principles in the Care and Use of Animals. The experi-
ment was approved by the local animal care committee.Blood processing
After 10 weeks of feeding, all animals were fasted for
16 hours and killed under anaesthesia, blood was col-
lected in heparinized vacutainer tubes from the heart
immediately. Blood samples were centrifuged at 1500 g
for 10 min at 4°C and the plasma was stored at -80°C
until analysis.Plasma lipids analysis
The plasma triglyeride (TG), total cholesterol (TC), low-
density lipoprotein cholesterol (LDL-C) and high-density
lipoprotein cholesterol (HDL-C) levels were determined
with commercial kits (Wako, Japan) by Hitachi 7020
full-automatic biochemical analyzer (Japan).Assay of plasma antioxidant capacity and lipid
peroxidation
Superoxide dismutases (SOD) activity was measured ac-
cording to the method of Kono [18]. Catalase (CAT) acti-
vity was estimated basing on the method of Goth [19].
Glutathione peroxidase (GPx) activity was measured by
the method of Sazuka [20]. The glutathione (GSH) content
was determined by the method of Moron [21]. The total
antioxidant capability (T-AOC) was assayed with com-
mercial kits (Nanjing Jiancheng Bioengineering Institute,
China). Thiobarbituric acid reactive substances (TBARS)
level was estimated by the method of Buege [22]. The
detection procedure of these enzymes activities has been
described in detail in our preceding report [23].Assay of plasma inflammatory markers
The plasma interleukin 6 (IL-6) and C-reactive protein
(CRP) levels were measured by means of commercially
available Rat CRP ELISA kit (Abcam, Cambridge, MA)
and Rat IL-6 ELISA kit (Abcam, Cambridge, MA), re-
spectively. All the procedures and conditions were con-
sistent with the instructions of these kits.Statistical analyses
Values are presented as mean ± SEM (standard error of
the mean). The data were analyzed by one-way ANOVA,
followed by the Fisher PLSD post hoc test if the overall
differences were significant (p < 0.05). All statistical ana-
lyses were performed using SPSS 13.0 statistical software
(SPSS Inc., Chicago, IL) and a difference was considered
significant when p < 0.05.
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Plasma antioxidative capacity and lipid peroxidation
H-FO + ASX-fed rats displayed significant SOD and GPx
activities when compared with HFD-fed animals. CAT
activities in M- and H-FO + ASX groups were remar-
kably higher than HFD group. Treatment with all doses
of FO + ASX significantly increased GSH levels and total
antioxidant capability. In addition, FO + ASX treatment
also had substantially reduced content of TBARS relative
to HFD diet (Figure 1).
Plasma lipids
Figure 2 shows that replacement of the HFD with M- and
H-FO +ASX significantly decreased plasma TG levels.
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Figure 1 Effects of FO and ASX combination on antioxidant enzymes
contents in plasma of rats fed a high-fat diet. HFD: high-fat diet group;
combination groups. Bars represent the mean ± SEM from 10 animals in eacomparable, rats administered with FO +ASX had mar-
kedly lower plasma TC and LDL-C levels than the HFD-
fed animals.
Plasma inflammatory
As seen in Figure 3, all three doses of FO + ASX treat-
ment reduced plasma levels of IL-6 and CRP when com-
pared with HFD diet.
Discussion
Although the exact mechanisms remain to be delineated,
oxidant stress [3], lipid abnormalities [4] as well as chronic
inflammation [5] have been identified as the main trigger
mechanisms of atherosclerosis. Atherosclerosis is funda-
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HFD L-FO+ASX M-FO+ASX H-FO+ASX
(SOD, CAT and GPx) activities, GSH levels, T-AOC and TBARS
L-. M- and H- FO + ASX: low, middle and high contents of FO and ASX
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Figure 2 Effects of FO and ASX combination on plasma TG, TC, LDL-C and HDL-C contents of rats fed a high-fat diet. HFD: high-fat diet
group; L-. M- and H- FO + ASX: low, middle and high contents of FO and ASX combination groups. Bars represent the mean ± SEM from 10 animals in
each group. * p < 0.05 and ** p < 0.01 compared to the HFD group.
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tion of the development of atherosclerosis. High-fat diets,
especially high-fat diet enriched with saturated fatty acid
exert more deleterious effect on CVD and can lead to ath-
erosclerosis [24], whereas the consumption of different
kinds of fatty acids have various effects on atherosclerotic
risk factors and even direct effects on atherogenesis
[24-26]. Because of rich in ALA, FO has been proven to
exert positive effect on atherosclerosis [25,26]. ASX is a
potent natural antioxidant and may play a beneficial role
in cardiovascular disease prevention [16]. In the study re-
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Figure 3 Effects of FO and ASX combination on IL-6 and CRP levels in
L-. M- and H- FO + ASX: low, middle and high contents of FO and ASX com
each group. ** p < 0.01 compared to the HFD group.combination on atherosclerosis risk factors in rats fed a
high-fat diet.
Oxidative stress represents an imbalance between the
free radical production and the antioxidant defense. The
relative excessive production of free radicals, which can
lead to oxidative damage to any biochemical component
including lipids, proteins and DNA, plays a causative
role in atherosclerosis [27]. For example, as a result of
oxidative stress, LDL can be modified to oxidized LDL
(oxLDL) which is clearly a critical factor in the athero-
sclerotic process and the cellular accumulation of oxi-
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plasma of rats fed a high-fat diet. HFD: high-fat diet group;
bination groups. Bars represent the mean ± SEM from 10 animals in
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pivotal pathogenetic factor and unifying mechanism for
atherosclerosis and other cardiovascular diseases [29].
Therefore, an efficient antioxidant defense system is re-
quired to counteract the deleterious effects of oxidative
stress. The primary antioxidant enzymes in mammals
include SOD which converts superoxide to hydrogen
peroxide, GPx and CAT which are responsible for con-
verting hydrogen peroxide to water [30]. GSH is a very
important non-enzymatic antioxidant which can react
directly with free radicals or act as an electron donor in
the reduction of peroxides catalyzed by GPx [31]. High
consumption of dietary fat is a known cause of increased
plasma oxidative stress [32], whereas in this experiment,
the combination of FO and ASX remarkably elevated
the plasma SOD, CAT and GPx activities as well as GSH
level, which led to the pronounced enhancement of total
antioxidant capability. As a result, lipid peroxidation
levels in plasma markedly declined with the supplement
of FO and ASX. However, FO itself is hardly thought to
have an authoritative antioxidative activity and further, it
may cause lipid peroxidation because of its susceptibility
to oxidation [12,13]. Thus, ASX is anticipated to impart
the entire antioxidative potency in this study. ASX has a
unique chemical structure featured by the presence of
polar moieties on both end of its polyene chain, and this
structural property of ASX confers much greater free
radical scavenging capability than β-carotene as well as
α-tocopherol [33-35]. Besides, ASX is able to restore the
activities of antioxidant enzymes SOD, CAT and GPx by
inducing, at least in part, the Nrf2 pathway and other
non-enzymatic antioxidants such as GSH, vitamins C
and E in plasma and other various tissues in pathological
conditions [36-38].
Hyperlipidemia is a well-known risk factor for arte-
riosclerosis as well as other cardiovascular disease and
treatment of hyperlipidemia retards progression of arterio-
sclerosis [39]. There is mounting evidence that high-fat
diet rich in saturated fatty acid leads to hyperlipidemia.
However, in the present experiment, the levels of TG, TC
and LDL-C in plasma declined in response to the con-
sumption of FO and ASX combination and both of FO
and ASX undoubtedly contributed to these beneficial
changes. ALA has been shown to suppress the expression
and activities of numerous hepatic fatty acid syntheses
such as fatty acid synthase (FAS), malic enzyme and
glucose 6-phosphate dehydrogenase [40,41], and hence
decrease fatty acid synthesis in liver. On the other hand,
ALA sharply enhances hepatic peroxisomal and mito-
chondrial fatty acid oxidation rate by increasing the ex-
pression and activities of a series of fatty acid oxidation
enzymes [41,42]. As a peroxisome proliferator-activated
receptor α (PPARα) agonist, ASX also shows the similar
action on inducing fatty acid oxidation [36,43]. Inaddition, the hypocholesterolemic effects of FO and
ASX are likely owing to elevated hepatic expression of
LDL receptor [9,36] as well as declined cholesterol bio-
synthesis [43,44].
Contemporary advances in cardiovascular research have
established a pivotal role for chronic inflammation in all
stages of atherosclerosis [45-47]. Various proinflammatory
risk factors such as oxLDL and infectious agents have a
capability to trigger the production of proinflammatory
cytokines which are deeply involved in the development
and progression of atherosclerosis. As primary proinflam-
matory cytokines, IL-6 and CRP are sensitive measures
of the burden of systemic atherosclerosis and extent of
atherosclerotic activity [48-50]. In the present experiment,
when the lard was replaced with the combination of FO
and ASX, both the plasma levels of IL-6 and CRP col-
lapsed, which implied that the FO and ASX combination
is fully competent to improve inflammation status. Sup-
porting our results, FO has been shown to suppress the
expression of various inflammatory cytokines such as
IL-6, IL-1, CRP and TNF-α via an activation of peroxi-
some proliferator-activated receptor γ (PPARγ) and/or a
reduction in NF-κB induced gene expression [6,10,51].
Similarly, ASX also exerts antiinflammatory properties by
suppressing NF-κB activation and thus decreased inflam-
matory markers levels in circulation [52,53].
In conclusion, supplement of FO and ASX combination
has satisfactory efficacy at ameliorating oxidative stress,
lipid profile and inflammation, which suggested that the
combination of FO and ASX might contribute to prevent
atherogenesis and then reduce the incidence of CVD. In
addition, the presence of astaxanthin in FO lowers the
lipid oxidation rate of FO and, on the other hand, astax-
anthin is stable in FO in room temperature [54]. This
makes the combination of FO and ASX very promising
functional food in cardiovascular health promotion.
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